ArticleBlood cell therapy2025
Therapy-related Myeloid Neoplasms After Autologous Stem Cell Transplantation for Lymphoma: A Single-Center Experience.
Article in Blood cell therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in lymphoma treatment, autologous hematopoietic stem cell transplantation (auto-HCT) remains essential in regions with limited access to novel therapies. Improved survival post-auto-HCT has led to an increased incidence of therapy-related myeloid neoplasms (t-MN). We conducted a retrospective analysis of adult patients (≥18 years) who underwent auto-HCT for lymphoma at King Hussein Cancer Center in Jordan between 2003 and 2020 with the goal of evaluating characteristics and outcomes of patients developing t-MN post-auto-HCT. We identified 407 patients with a median follow-up of 5.8 years. The median age at auto-HCT was 34.6 years, 54.9% were males, 65.3% had Hodgkin lymphoma, and 41.1% were refractory to first-line treatment. dexamethasone, ara-C, cisplatin (DHAP) was the most common salvage regimen (47.8%). At the time of auto-HCT, 39.7% were in complete remission. BCNU, etoposide, ara-C, melphalan (BEAM) was the most common conditioning regimen 91.9%. The 5-year overall survival (OS) was 64.4%. Thirteen patients (3.2%) developed t-MN (5 acute myeloid leukemia, 8 myelodysplastic syndrome) with a median onset of 3.25 years post-auto-HCT. The median OS post t-MN diagnosis was 6 months. Patients with t-MN were older (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.